Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 80,199 |
|
|||||
| News | - | ||||||
| Day High | 1.50 | Low High |
|||||
| Day Low | 1.40 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Scynexis Inc | SCYX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.05 | -3.40% | 1.42 | 15:06:54 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.47 | 1.40 | 1.50 | 1.47 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 422 | 80,199 | $ 1.44 | $ 115,620 | - | 1.35 - 3.87 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:06:54 | 24 | $ 1.42 | USD |
Scynexis Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 52.46M | 37.21M | - | 140.14M | 67.04M | 1.80 | 0.78 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Scynexis News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SCYX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.66 | 1.67 | 1.40 | 1.51 | 213,987 | -0.24 | -14.46% |
| 1 Month | 1.43 | 1.86 | 1.35 | 1.54 | 249,129 | -0.01 | -0.70% |
| 3 Months | 1.85 | 2.17 | 1.35 | 1.67 | 205,412 | -0.43 | -23.24% |
| 6 Months | 1.98 | 2.37 | 1.35 | 1.76 | 225,903 | -0.56 | -28.28% |
| 1 Year | 3.14 | 3.87 | 1.35 | 2.43 | 316,342 | -1.72 | -54.78% |
| 3 Years | 7.88 | 11.30 | 1.15 | 3.91 | 406,055 | -6.46 | -81.98% |
| 5 Years | 1.75 | 11.30 | 0.50 | 3.15 | 472,879 | -0.33 | -18.86% |
Scynexis Description
| SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. |
